XBiotech Inc. is a biotechnology company involved in the development, production, and commercialization of therapeutic antibodies designed to treat serious human diseases. This company focuses on its proprietary True Human™ antibodies, which are derived from natural human immunity rather than genetically engineered models. The primary purpose of these therapies is to target chronic inflammatory conditions, infectious diseases, and cancer while minimizing potential side effects associated with synthetic antibodies. Founded in 2005 and headquartered in Austin, Texas, XBiotech's research and innovation seek to impact sectors such as healthcare and pharmaceuticals significantly. The company's efforts are centered on advancing medicine by using the human body's natural immune responses to deliver safer and more effective treatments. XBiotech's work represents a pivotal role in the biotechnology landscape as it pushes forward with groundbreaking research aimed at changing therapeutic approaches to human health. By leveraging innovative biotechnology, XBiotech Inc. continues to contribute to developments that could reshape patient care across various medical fields.